Onasemnogene abeparvovec gene therapy for spinal muscular atrophy: A cohort study from the United Arab Emirates

Documenti analoghi

• Safety of risdiplam in spinal muscular atrophy patients after short‐term treatment with nusinersen
  di: Yue Yan, et al.
  Pubblicazione: (2024)
• Six‐minute walk test as outcome measure of fatigability in adults with spinal muscular atrophy treated with nusinersen
  di: Alessandra Govoni, et al.
  Pubblicazione: (2024)
• Transverse interlaminar ultrasound‐guided C1‐C2 puncture for the intrathecal administration of nusinersen in patients with spinal muscular atrophy
  di: Qing Yuan, et al.
  Pubblicazione: (2024)
• Ultrasound assisted versus landmark based intrathecal administration of nusinersen in adults with spinal muscular atrophy disease: A randomized trial
  di: Bruno Antonio Zanfini, et al.
  Pubblicazione: (2024)
• Secondary outcomes of scoliosis surgery in disease‐modifying treatment‐naïve patients with spinal muscular atrophy type 2 and nonambulant type 3
  di: Chiara Brusa, et al.
  Pubblicazione: (2024)